Compare BioNTech SE - ADR (BNTX) vs Clorox Co (CLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Clorox Co — how do they compare? BioNTech SE - ADR trades at $92.59 (market cap $23.31B), while Clorox Co trades at $105.7 (market cap $13.09B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Clorox Co pays a 4.62% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CLX | |
|---|---|---|
Market Cap | $23.31B | $13.09B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $127.16 |
52-Week Low | $83.89 | $86.12 |
Enterprise Value | $6.60B | $18.47B |
Dividend Yield | — | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Clorox (CLX) trades at $107.70, up 2.43% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations, though Q4 2025 missed. The company maintains solid profitability with a net margin of 8.74% and ROE of 285.64%, but faces high P/B of 145.45. News highlights Q4 sales beat and a dividend increase to $1.25 per share, while inflation and consumer value-seeking pose challenges.
Outlook is mixed: improving market share and strategic initiatives support growth, but inflation and competitive pressures risk margins. Analyst consensus is cautious with a hold-heavy rating and $97.50 price target below current levels. Key risks include supply-chain inflation and weak organic sales, requiring careful monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
